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Abstract: Lung cancer is the leading cause of cancer death, and approximately 15% of all lung cancer patients have small-cell lung 
cancer (SCLC). Although second-line chemotherapy can produce tumor regression, the prognosis is poor. Amrubicin hydrochloride 
(AMR) is a synthetic anthracycline anticancer agent and a potent topoisomerase II inhibitor. Here, we discuss the features of SCLC, the 
chemistry, pharmacokinetics, and pharmacodynamics of AMR, the results of in vitro and in vivo studies, and the efficacy and safety of 
AMR monotherapy and combination therapy in clinical trials. With its predictable and manageable toxicities, AMR is one of the most 
attractive agents for the treatment of chemotherapy-sensitive and -refractory relapsed SCLC. Numerous studies are ongoing to define 
the applicability of AMR therapy for patients with SCLC. These clinical trials, including phase III studies, will clarify the status of AMR 
in the treatment of SCLC.
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small-cell Lung cancer
Lung cancer is the leading cause of cancer death, and 
approximately 15% of all patients with lung cancer 
are diagnosed with small-cell lung cancer (SCLC). 
After an apparently successful frontline therapy, most 
patients experience recurrence because of intrinsic or 
acquired resistance. At the time of recurrence, many 
SCLC  patients  are  potential  candidates  for  further 
therapy.  Although  second-line  chemotherapy  has 
been shown to cause tumor regression, many respond-
ers do not live long.1 The median survival time (MST) 
is rarely more than 12 months and is usually less than 
6 months after second-line therapy.2 Treatment options 
for patients with recurrent SCLC include monothera-
pies of etoposide (VP-16),3 oral VP-16,4 teniposide,5 
vinorelbine,6,7 irinotecan,8 paclitaxel,9 gemcitabine,10,11 
pemetrexed,12,13 picoplatin,14 topotecan,15 etc.; combi-
nation  therapies  of VP-16  and  cisplatin  (CDDP),16 
doxorubicin+paclitaxel,17  carboplatin  (CBDCA)+ 
paclitaxel,18 CBDCA+irinotecan (CPT-11),19 CDDP+ 
CPT-11,20  CPT-11+VP-16,21  CPT-11+gemcitabine,22 
topotecan+CDDP,23  vincristine+doxorubicin+cyclo-
phosphamide,24 VP-16+CDDP+ifosfamide,25   paclitaxel+ 
ifosfamide+CDDP,26  CPT-11+CDDP+mitomycin,27 
etc.; or re-challenge with front-line chemotherapy.16
The  response  rate  (RR)  of  recurrent  SCLC  to 
  second-line  chemotherapy,  or  to  re-challenge  with 
frontline chemotherapy, is highly dependent on the 
time between the completion of frontline chemother-
apy and tumor recurrence. Patients who fail to respond 
to frontline chemotherapy or who relapse shortly after 
completion of frontline chemotherapy tend to have 
poor  survivals,  while  patients  who  relapse  6  to 
12 months after completion of frontline chemother-
apy have RRs as high as 60% and better survivals.28
By analogy to chemo-sensitive cancers, including 
SCLC,  two  main  categories  of  patients  receiving 
  second-line  chemotherapy  have  been  described: 
  “chemotherapy-sensitive relapse” and “chemotherapy- 
refractory  relapse”.  Chemotherapy-sensitive  relapse 
patients have a frontline response that lasts more than 
90  days  after  the  completion  of  treatment.  These 
patients receive the greatest benefit from second-line 
chemotherapy. In contrast, chemotherapy-refractory 
relapse patients comprise those who either did not 
respond to frontline chemotherapy, or responded ini-
tially but relapsed within 90 days of its completion.29 
New drugs are urgently needed to control SCLC more 
effectively, particularly for chemotherapy-refractory 
relapse patients.
Anthracyclines: Doxorubicin, 
epirubicin, and Amrubicin
Anthracyclines, such as daunorubicin and doxoru-
bicin, are widely used in the treatment of a variety 
of  cancers.  However,  the  cumulative  dose-limiting 
cardiotoxicity of doxorubicin is a major obstacle to 
its use,30 and great efforts have been made to discover 
means of ameliorating, preventing and delaying this 
side-effect.
A major metabolic pathway of anthracyclines is 
the reduction of the C-13 carbonyl group to a hydroxyl 
group by carbonyl reductase.31 This step is generally 
regarded as an inactivation, because the 13-hydroxyl 
metabolites of doxorubicin, epirubicin and daunoru-
bicin are much less cytotoxic than the corresponding 
parental  drugs,  unlike  idarubicinol  and  idarubicin, 
whose metabolites are equipotent.32
Amrubicin  hydrochloride  (AMR;  (+)-(7S,  9S)- 
9-acetyl-9-amino-7-[(2-deoxy-b-D-erythro-
pentopyranosyl)-oxy]-7,8,9,10-tetrahydro-6, 
11-  dihydroxy-5,12-naphthacenedione hydrochloride) 
is a novel synthetic 9-aminoanthracycline derivative, 
with a structure similar to doxorubicin. (Fig. 1) AMR 
is currently approved for the treatment of SCLC and 
non-small-cell  lung  cancer  (NSCLC)  in  Japan.  Its 
antitumor activity was found to be superior to that of 
doxorubicin in experimental therapeutic models using 
human tumor xenografts.33 In addition, AMR showed 
much less cardiotoxicity than doxorubicin in chronic 
experimental models using rabbits and dogs.34,35
Similar to other anthracyclines, AMR is metabo-
lized to amrubicinol (AMR-OH), through reduction of 
its C-13 ketone group to a hydroxy group.36   However, 
in contrast to other anthracyclines, the in vitro cyto-
toxic activity of AMR-OH is 18–220 times more pot-
ent than that of its parent compound, AMR.31
In mice experiments, Noguchi et al showed that 
AMR-OH has more potent antitumor activity than 
its parent compound, AMR.37 The levels of AMR-OH 
in the tumors of these mice were higher than doxo-
rubicin levels in doxorubicin-treated mice. In con-
trast, the levels of AMR and AMR-OH were lower 
than  those  of  doxorubicin  in  several  non-tumor Amrubicin for second-line treatment of SCLC
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  tissues, including the heart. In addition, by   measuring 
the  concentrations  of  AMR-OH  in  seven  human 
tumor xenografts after the administration of AMR,   
a good correlation was found between the level of 
AMR-OH in the tumor and the efficacy of AMR 
in vivo.38 Thus, AMR appears to be a very promising 
antitumor agent: its potent antitumor activity is due 
to high levels of the active metabolite in the tumor, 
and its non-  hematological toxicities, mainly cardiac 
toxicities, can be easily controlled because of the 
restricted  distribution  of  the  active  metabolite  in 
non-tumor tissues.
In vitro and In vivo studies
Several studies have reported a comprehensive assess-
ment of the clinical uses of AMR in combination with 
chemotherapeutic  agents  analyzed  by  the  isobolo-
gram method39 or by the combination index values.40 
We reported in vitro studies in the SCLC cell line 
SBC-3 and in the NSCLC cell line Ma-1—that CDDP 
enhanced the effect of AMR-OH, and that AMR-OH 
enhanced  the  formation  of  CDDP-induced  DNA 
interstrand cross-links.41 Another group reported the 
combination effects of AMR with other anticancer 
agents analyzed by the isobologram method in the 
T-cell leukemia cell line MOLT-3 and the human oste-
osarcoma  cell  line  MG-63.42  In  MOLT-3  cells, 
AMR-OH had additive effects with bleomycin, VP-16, 
doxorubicin,  CDDP,  mitomycin-C,  4-  hydroperoxy 
ifosfamide,  5-fluorouracil,  cytarabine,  and  vincris-
tine, whereas it had mainly protective (marked antag-
onistic)  effects  with  methotrexate.  In  MG-63  cells, 
AMR-OH had additive effects with bleomycin, VP-16, 
doxorubicin,  CDDP,  mitomycin-C,  4-hydroperoxy 
ifosfamide;  mainly  sub-  additive  (mild  antagonistic) 
effects with 5-fluorouracil and cytarabine; and mainly 
protective (marked antagonistic) effects with vincris-
tine and methotrexate. Takigawa et al reported that 
AMR-OH was completely cross-resistant to doxoru-
bicin and VP-16 in experiments using the   doxorubicin- 
resistant  SCLC  cell  line  SBC-3/ADM  and  the 
VP-16-resistant  SCLC  cell  line  SBC-3/ETP.43 
  Simultaneous exposure of the irinotecan (CPT-11)-
resistant SCLC cell line SBC-3/SN-38 to AMR-OH 
and CDDP showed a synergistic effect when analyzed 
by the combination index values. Simultaneous expo-
sure of the CDDP-resistant SCLC cell line SBC-3/
CDDP to AMR-OH resulted in synergistic effects.44 
In   addition, multi-drug combination effects have been 
reported for AMR-OH in combination with chemo-
therapeutic agents in vitro models when analyzed by 
the combination index values and in human lung can-
cer xenograft models.45 In these experiments, human 
SCLC cell lines, NSCLC cell lines, a breast cancer 
cell line, and human gastric cancer cell lines were 
simultaneously  exposed  to  two  agents  for  3  days. 
AMR-OH showed synergistic effects for the simulta-
neous use of CPT-11, CDDP, gefitinib and trastuzumab; 
additive  effects  with  vinorelbine;  and  antagonistic 
interactions with gemcitabine. As for AMR, synergis-
tic  effects  were  found  for  simultaneous  use  with 
CPT-11, gefitinib and trastuzumab; and additive effects 
were  demonstrated  with  CDDP  and    vinorelbine.  In 
human lung cancer xenograft models, AMR adminis-
tered  intravenously  at  25  mg/kg  substantially  pre-
vented  the  growth  of  five  out  of  six  human  lung 
cancer xenografts established in athymic nude mice. 
  Synergistic effects were obtained for the simultaneous 
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Figure 1. Chemical structures of amrubicin and amrubicinol.Kimura et al
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use of AMR-OH with CDDP, CPT-11, gefitinib and 
  trastuzumab.  The  combination  of  AMR-OH  with 
gemcitabine was antagonistic. As just described, the 
combination with AMR and some chemotherapeutic 
agents  has  theoretical  advantages  and  have  proven 
anticancer efficacy. A clinical outcome includes both 
antitumor response and normal tissue toxicity from a 
variable drug   exposure, whereas in vitro models rep-
resent only antitumor response. Further studies are 
warranted on AMR in combination with chemothera-
peutic agents in clinical settings.
Mechanisms of Action  
of Anthracyclines and AMR
DNA topoisomerases I and II are functionally related 
nuclear enzymes that, in concert, catalyze the relax-
ation of supercoiled chromosomal DNA during DNA 
replication. The relaxation of DNA by topoisomerase   
I or II involves the transient single or double strand 
breakage of DNA, followed by strand passage and 
relegation of the DNA strand. They are extensively 
involved  in  DNA  replication,  transcription,  and 
recombination, and in sister chromatin segregation, 
and as such are essential in maintaining cell   viability.46 
Mammalian DNA topoisomerase II is the primary tar-
get of a number of antitumor agents such as doxoru-
bicin, daunorubicin, VP-16 and amsacrine.47 These 
agents interfere with the breakage–reunion reaction of 
DNA topoisomerase II by trapping a covalent enzyme– 
DNA complex, termed “the cleavable   complex”, in 
which DNA strands are broken and their 5′ termini 
are  covalently  linked  to  the  protein.  AMR  and 
AMR-OH also stabilize the topoisomerase II-DNA 
complex,36 but the mechanisms of cell killing by AMR 
and AMR-OH are not understood.
combination Therapy with 
Topoisomerase I and II Inhibitors
Studies have shown that the use of a combination of 
topoisomerase I and II inhibitors completely arrests 
both  DNA  and  RNA  synthesis,  which  results  in 
  synergistic cytotoxicity. Preclinical studies have dem-
onstrated that resistance to CPT-11, a   topoisomerase   
I inhibitor, is often accompanied by the upregulation 
of  topoisomerase  II,  causing  hypersensitivity  to 
agents that target topoisomerase II.48–50 Consequently, 
the  scheduling  of  therapy  with  a    combination  of 
CPT-11 and a topoisomerase II   inhibitor is critical for 
success:51 sequential administration of CPT-11 fol-
lowed by a topoisomerase II inhibitor led to synergis-
tic cytotoxicity, while concurrent administration led 
to antagonism.52
Clinical information on the combination of topoi-
somerase I and II inhibitors in the treatment of patients 
with  SCLC  is  limited.  Masuda  et  al  conducted  a 
phase  II  study  on  refractory  or  relapsed  SCLC.21 
Twenty-five patients were treated at 4-weekly inter-
vals with CPT-11 at a dose of 70 mg/m2 on days 1, 8, 
and 15, plus VP-16 at a dose of 80 mg/m2 on days 1–3, 
with granulocyte colony-stimulating factor (G-CSF) 
support. The overall RR was 71% and the MST was 
8.9 months. Another phase II study was reported by 
Goto et al.53 Forty patients with sensitive relapsed 
SCLC were treated with CPT-11 at a dose of 90 mg/m2 
on day 1 in weeks 2, 4, 6, and 8, CDDP at a dose of 
25 mg/m2 on day 1 weekly for 9 weeks, and VP-16 at 
a dose of 60 mg/m2 on days 1–3 of weeks 1, 3, 5, 7 
and  9,  with  G-CSF  support.  The  overall  RR  was 
78%  and  the  MST  was  11.8  months.  Quoix  et  al 
reported a phase II study investigating the efficacy 
and safety of topotecan in combination with either 
CDDP or VP-16 in untreated extensive disease (ED)-
SCLC.54 Patients were randomized to treatment with 
T/C (topotecan at 1.25 mg/m2 on days 1–5, CDDP at 
50 mg/m2 on day 5) or T/E (topotecan at 0.75 mg/m2 
on days 1–5, VP-16 at 60 mg/m2 on days 1–5) every 
21 days. The RRs were similar for the T/C (63.4%) 
and the T/E (61.0%) groups. The MST was 9.6 months 
for the T/C group and 10.1 months for the T/E group. 
Furthermore, Mok et al conducted a phase I–II study 
of the sequential administration of topotecan and oral 
VP-16, with alternation of the drug sequence with 
each consecutive cycle, and compared the hemato-
logic toxicity between the two sequences.55 Thirty-six 
patients (21 with limited disease and 15 with exten-
sive disease) received a total of 173 courses of sequen-
tial combination chemotherapy (topotecan followed 
by VP-16, and VP-16 followed by topotecan). There 
was no significant difference in hematologic toxicity 
between  the  two  sequences.  The  combination  of 
topoisomerase  I  and  II  inhibitors  was  considered 
highly effective and well tolerated in the treatment 
of SCLC.Amrubicin for second-line treatment of SCLC
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pharmacokinetics and 
pharmacodynamics
In  a  pharmacokinetic  study  examining  the  time- 
concentration  profiles  of AMR  and AMR-OH,  the 
plasma concentration curves fitted a three-  compartment 
open model.37 AMR was metabolized to AMR-OH by 
human  tumor  cells,  and  substantial  amounts  of 
AMR-OH were found in cells after a five-hour incu-
bation  with  AMR  in  several  cancer  cell  lines.31 
AMR-OH is less susceptible than AMR to further 
metabolism  or  is  retained  in  tissues  for  a  longer 
  period.37 It was also found that the ratio of AMR-OH 
to AMR plasma levels was approximately 0.1, from 
1 h after administration.37 Although the plasma con-
centration curve of AMR exhibited a high peak in the 
α/β phase and a downward slope in the γ phase, that 
of AMR-OH exhibited a slight or low peak in the α/β 
phase and a continuous long plateau in the γ phase. 
The  half-lives  in  the  terminal  phase  (T1/2γ)  of 
AMR and AMR-OH, after administration of 40 mg/m2 
AMR on day 1, were 6.2 ± 2.0 and 16.2 ± 4.66 h, 
respectively.56 Another study reported the T1/2γ of 
AMR and AMR-OH, after administration of 30 mg/m2 
AMR on day 3, to be 2.2 ± 0.19 and 23.2 ± 18.26 h, 
respectively.57
The pharmacodynamic profiles in a phase I trial 
showed the relationships between the area under the 
concentration–time curve (AUC), the maximum drug 
concentration  (Cmax)  of  plasma AMR,  and  clinical 
efficacy. The AUC0–24 of AMR was significantly cor-
related with the AUC of AMR-OH.56 The AUC and 
Cmax of plasma AMR were related to the duration of 
grade 4 neutropenia.58 Another pharmacological study 
reported a significant relationship between the grade 
of leukopenia and the AUC of AMR-OH.59   Previously, 
we reported a significant relationship between hema-
tological toxicity and the plasma trough concentra-
tion  of  AMR-OH.60  Significant  relationships  were 
observed between the levels of AMR-OH on day 4 
and the toxicity grades of leukopenia, neutropenia, 
and anemia (p = 0.018, p = 0.012, and p = 0.025, 
respectively). The thrombocytopenia grade exhibited 
a tendency towards correlation with AMR-OH levels 
on day 4 (p = 0.081). The plasma concentration of 
AMR-OH on day 4 was positively correlated with 
percent change in neutrophil count in the group com-
prising all patients, as well as in patients treated with 
AMR alone and in patients co-administered CDDP. 
The plasma concentration of AMR or AMR-OH cor-
related with hematological toxicity in patients treated 
with  AMR.  Such  pharmacological  studies  might 
facilitate the prediction of hematological toxicity.
clinical Trials with Amrubicin 
Hydrochloride Monotherapy
Phase I studies
At first, a dose escalation study of AMR given on 
day 1 of every 3-week period was performed in a 
phase I setting for 19 patients with advanced cancer.61 
Twenty-nine  evaluable  courses  of  treatment  were 
conducted in groups, with doses increasing from 10 
to 130 mg/m2. Myelosuppression was the dose-  limiting 
toxicity  (DLT)  and  the  maximum  tolerated  dose 
(MTD) was 130 mg/m2. The recommended dose (RD) 
and schedule for a phase II trial was 100 mg/m2 every 
3 weeks.
Next, as a 5-min intravenous infusion for three 
consecutive days, a phase I–II study was conducted 
on  patients  with  previously  untreated  NSCLC.62 
The MTD was 50 mg/m2/day and the DLTs were leu-
kopenia, neutropenia, thrombocytopenia, and gastro-
intestinal complications. The RD in the phase II study 
was 45 mg/m2 for three consecutive days every 3 weeks. 
A phase I study for refractory or relapsed lung cancer 
(NSCLC  or  SCLC)  patients  was  conducted  by 
  Okamoto et al.56 Fifteen patients were treated with 
AMR at doses of 30, 35, or 40 mg/m2 on three con-
secutive days every 3 weeks. Grade 4 neutropenia 
was observed in 67% of patients, and the MTD and 
RD  were  determined  as  40  mg/m2  and  35  mg/m2, 
respectively. Similarly, Igawa et al conducted a dose-
escalation study of second-line and third-line settings 
for SCLC.63 The RDs were determined to be 40 mg/m2 
and 35 mg/m2, respectively.
Phase II studies
Yana et al conducted a phase II study on previously 
untreated ED-SCLC patients.64 AMR was adminis-
tered  intravenously  at  a  dose  of  45  mg/m2/day  on 
three  consecutive  days  every  3  weeks.  Of  the 
33 patients, the overall RR and MST were 75.8% and 
11.7 months, respectively. The 1-year and 2-year sur-
vival  rates  were  48.5%  and  20.2%,  respectively; 
  however, hematologic toxicities were severe: grade Kimura et al
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3/4 neutropenia, anemia, and thrombocytopenia were 
observed in 84.8%, 78.8%, and 39.4% of patients, 
respectively.
The efficacy and safety of AMR in patients with 
previously  treated  SCLC  have  been  demonstrated 
in several phase II studies (Table 1). In Japan, five 
phase  II  studies  have  been  conducted  at  different 
doses of AMR for relapsed SCLC. In the first three 
studies described below, AMR was administered as a 
single  agent  at  40  mg/m2  for  three  consecutive 
days.65–67 In the first study, conducted by our group, 
19  patients  were  treated  with  AMR.  The  RRs  in 
7   sensitive and 12 refractory relapse patients were 
43%, and 33%, respectively.65 In the second study, 
conducted by Onoda et al, the RR and MST in sensi-
tive  relapse  and  refractory  relapse  patients  were 
52% and 11.6 months, and 50% and 10.3 months, 
respectively.66 In the third study, a randomized phase II 
trial comparing topotecan and AMR was conducted.67 
Sixty patients were randomly assigned to either AMR 
or  topotecan,  and  59  (36  sensitive  relapse  and  23 
refractory relapse patients) were   evaluable. For AMR 
treatment, the RRs of overall, sensitive relapse, and 
refractory relapse patients were 38%, 53%, and 17%, 
respectively.  The  median    progression-free  survival 
time (PFS) and MST were 3.5 months and 8.1 months, 
respectively.  In  the  fourth  study,  conducted  by 
Kato et al, 45 mg/m2 of AMR was administered on days 
1–3, every 3 weeks.68 Thirty-four patients were treated 
with AMR, and there were four complete responses 
(CRs) and 14 partial responses (PRs), with an RR of 
53%. The RR and MST among sensitive relapse and 
refractory relapse patients were 50% and 10.4 months, 
and 60% and 6.8 months, respectively. The fifth study 
was conducted by Kaira et al, in which 35 mg/m2 of 
AMR  was  administered  to  both  SCLC  and  NSCLC 
patients.28 In this study, 29 relapsed SCLC patients were 
enrolled, and the RR and MST among sensitive relapse 
and  refractory  relapse  patients  were  60%  and 
12.0 months, and 37% and 11.0 months,   respectively. 
These five studies resulted in an RR of the sensitive 
relapse  patients  in  this  fifth  report  of  50.0%–53.0%,  and  that 
of refractory relapse patients of 17.0%–60.0%. AMR is 
a  promising  therapeutic  for    chemotherapy-sensitive 
relapse patients as well as for chemotherapy-refractory 
relapse patients. To support the efficacy for chemother-
apy-refractory relapse patients, a phase II study of AMR 
in patients with SCLC that is refractory or relapsed 
within  90  days  of  completing  previous  treatment  is 
ongoing in Japan.
Two phase II studies have been conducted outside 
Japan.  In  the  first  study,  conducted  in  the  USA, 
76 sensitive relapse patients were randomly assigned 
to either AMR or topotecan.69 The RR, the median 
PFS and MST for AMR were 36%, 4.3 months and 
9.3  months,  respectively.  In  the  second  study,  75 
refractory relapse patients were treated with 40 mg/m2 
AMR on three consecutive days every 3 weeks.29 The 
RR and MST were 21% and 6.0 months, respectively. 
The RRs and MSTs in these two studies conducted 
outside Japan were considerably lower than those of 
the Japanese phase II studies.
Interestingly, there were two phase II studies com-
paring topotecan and AMR conducted in Japan and 
USA.67,69 In the Japanese study, topotecan was admin-
istered at a dose of 1.0 mg/m2 on days 1–5, every 
3 weeks. For topotecan treatment, the RRs of overall, 
sensitive relapse and refractory relapse patients were 
13%, 21%, and 0%, respectively. The median PFS 
and  MST  were  2.2  months  and  8.4  months, 
  respectively. AMR had significantly better overall RR 
rates than topotecan (p = 0.039). However, the hema-
tologic  and  nonhematologic  toxicities  worse  than 
grade 3 were more frequent in the AMR arm. In terms 
Table 1. Phase II studies of amrubicin monotherapy for 
recurrent SCLC.
Authors Dose  
(mg/m2)
n RR 
(%)
pFs 
(months)
MsT 
(months)
sensitive relapse
Kudoh et al65 40 7 42.8 NA NA
Onoda et al66 40 44 52 4.2 11.6
Inoue et al67 40 17 53 3.9 9.9
Kato et al68 45 24 50 NA 10.4
Kaira et al28 35 10 60 4 12
Jotte et al69 40 50 44 4.6 9.3
Refractory relapse
Kudoh et al65 40 12 33.3 4 8.3
Onoda et al66 40 16 50 2.6 10.3
Inoue et al67 40 12 17 2.6 5.3
Kato et al68 45 10 60 NA 6.8
Kaira et al28 35 19 36.8 4 11
ettinger et al29 40 75 21 3.2 6
Abbreviations: RR, response rate; PFS, progression free survival;   
MST, median survival time.Amrubicin for second-line treatment of SCLC
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of overall survival, there was no statistical difference 
between topotecan and AMR. However, a significant 
difference in overall survival was observed between 
patients treated with AMR and those without AMR 
(p , 0.001). The USA study was conducted only 
for  sensitive  relapse  patients,  and  topotecan  was 
administered at a dose of 1.5 mg/m2 on days 1–5, 
every 3 weeks. The RR, the median PFS and MST for 
  topotecan  were  8%,  3.5  months,  and  8.9  months, 
respectively. AMR gave significantly better overall 
RR rates than topotecan (p , 0.012). The most com-
mon grade $3 adverse events with AMR vs.   topotecan 
were neutropenia (53% vs. 74%), thrombocytopenia 
(31%  vs.  52%)  and  leukopenia  (27%  vs.  30%). 
  Statistical  analyses  in  terms  of  overall  survival 
between topotecan and AMR were not reported. As a 
result, AMR had better overall RR rates than   topotecan. 
There is no difference between topotecan and AMR 
in the terms of overall survival. However, consider-
ing subsequent chemotherapy after the enrollment in 
these studies, AMR may have more influence than 
topotecan on overall survival.
side effects
The  most  frequent  toxicity  was  myelosuppression. 
Previous phase II studies of AMR monotherapy for 
treated  SCLC  found  that  treatment  was  associated 
with a high incidence of bone marrow suppression or 
grade 3 or 4 hematologic toxicity.29,66,67 These toxici-
ties comprised neutropenia (83%), thrombocytopenia 
(20%), and anemia (33%) in Onoda et al’s report; 
neutropenia  (93%),  thrombocytopenia  (28%),  and 
anemia (21%) in Inoue et al’s report; and neutropenia 
(66.7%),  thrombocytopenia  (40.6%),  and  anemia 
(30.4%)  in  Ettinger  et  al’s  report.  Consistent  with 
these results, the major adverse events in our own 
study were grade 3 or 4 hematologic toxicities includ-
ing neutropenia (85%), leukopenia (85%), thrombo-
cytopenia (32%), and anemia (42%).65
Non-hematologic toxicities were generally mild, 
except for grade 3 febrile neutropenia. Onoda et al 
described  the  most  frequent  grade  3  or  4  non- 
hematologic toxicities as anorexia (15%), asthenia 
(15%), hyponatremia (8%), nausea (5%), and febrile 
neutropenia (5%).66 In Inoue et al’s report, the most 
frequent  grade  3  or  4  non-hematologic  toxicities 
were  fatigue  (17%),  febrile  neutropenia  (14%), 
infection (10%), anorexia (7%), stomatitis (3%), and 
nausea (3%).67 According to Ettinger et al, the most 
common grade 3 or 4 non-hematologic toxicity was 
fatigue (21.7%).29 Grade 3 or 4 febrile neutropenia 
was seen in 11.6%. No cardiotoxicity, except for one 
transient  atrial  fibrillation,  was  observed  among 
these three reports. No treatment deaths occurred in 
our study,65 or in that of Onoda et al.66 However, 
there  was  one  treatment-related  death,  resulting 
from neutropenic infection, in the AMR arm of Inoue 
et al’s study,70 and there was one patient death each 
of pulmonary hemorrhage, acute myocardial infarc-
tion, and interstitial lung disease in the Ettinger et al 
study.29
clinical Trials with Amrubicin-based 
combination Therapy
Rationale for combination therapy
As shown in Table 2, AMR has been used in clinical 
trials  in  double  combination  regimens.  There  is  a 
clear need for non-cross-resistant therapeutic options. 
In vitro antitumor synergy with many chemothera-
peutic agents may indicate AMR as an ideal candidate 
for use in combination therapy.
Topoisomerase I Inhibitors  
and Amrubicin
CPT-11 and AMR have been used in three phase I 
studies of patients with advanced NSCLC.57,71,72 In 
the first study,57 both drugs were administered on days 
1 and 8, and the MTDs of CPT-11 and AMR were 100 
and  45  mg/m2,  respectively.  This  level  had  3  of   
4 patients with DLTs (persistence of grade 4 neutro-
penia and grade 4 leukopenia, persistence of grade 4 
neutropenia,  and  grade  3  febrile  netropenia).  The 
RDs of CPT-11 and AMR were 100 and 40 mg/m2, 
respectively.  In  the  second  study,71  patients  were 
treated  at  3-weekly  intervals  with  dose-escalated 
AMR  (days  1–3)  plus  a  fixed  dose  of  60  mg/m2 
CPT-11 (days 1 and 8). The 30 mg/m2 AMR dose was 
one dose level above the MTD, since diarrhea and 
leukopenia were the DLTs. The RDs are 60 mg/m2 
of CPT-11 (days 1 and 8) and 25 mg/m2 of AMR 
(days 1–3), administered every 3 weeks. The third 
study was a dose escalation study of AMR in combi-
nation  with  fixed-dose  CPT-11  in  patients  with Kimura et al
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ED-SCLC  reported  by  Oshita  et  al.72  Previously 
untreated patients with ED-SCLC were treated with 
CPT-11  at  60  mg/m2  on  day  1  and  dose-escalated 
AMR on days 1–3, with prophylactic subcutaneous 
G-CSF on days 5–9 every 2–3 weeks. At 40 mg/m2 
AMR, DLTs such as grade 4 neutropenic fever were 
observed, and therefore this dose level was defined as 
the MTD, with an overall RR of 100%.
A  phase  I  study  of  combination  topotecan  and 
AMR therapy in SCLC patients with relapsed or ED-
SCLC was reported by Shibayama et al.58 Topotecan 
and AMR were administered on days 1–5 and on days 
3–5 every 4 weeks, respectively. DLTs (grade 4 neu-
tropenia lasting for more than 4 days, grade 3 febrile 
neutropenia,  or  grade  4  thrombocytopenia)  were 
observed  at  0.75  mg/m2  topotecan  and  40  mg/m2 
AMR, and thus these were determined to be the MTDs. 
An objective response was observed in six patients 
(67%). The phase II study of the same regimen every 
3  weeks  for  chemo-naïve  or  relapsed  SCLC  was 
reported.73 The RRs were obtained in 23 (74%) of the 
31  chemo-naïve  and  12  (43%)  of  the  28  relapsed 
patients. Myelosuppresion was the principal toxixity 
with  grade  4    leukopenia,  neutropenia,  thrombocy-
topenia  and  anemia  of  46%,  80%,  25%  and  7%, 
respectively.  Grade  3–4  febrile  neutropenia  was 
observed in 41% of the patients, of whom one patient 
further developed Grade 5 septic shock. Other grade 
3  or  greater  non-hematological  toxicities  included 
diarrhea, pneumonitis, vomiting, fatigue and hypona-
tremia in 2%, 3%, 5%, 9% and 2%, respectively. One 
patient each developed fatal diarrhea and pneumonitis. 
At the time of data analysis with a median follow-up 
time of 43.2 months, MST and median PFS were 14.9 
and 5.3 months in the chemo-naïve patients and 10.2 
and 5.1 months in the relapsed patients, respectively. 
Other ongoing studies include a phase II study of 
CPT-11  plus  CDDP  followed  by AMR  in  patients 
with ED-SCLC, and a phase I–II study of AMR and 
CPT-11 in patients with advanced SCLC. The combi-
nation of topoisomerase I Inhibitors and AMR seemed 
effective  for  SCLC,  despite  the  severe  toxicity 
  profiles.  Their  preliminary  findings  contradict  the 
preclinical evidence from in vitro studies that showed 
Table 2. Clinical trials with amrubicin-based combination therapy.
Authors Histology  phase patient selecion Drugs schedule  
(day) 
Interval 
(weeks)
MTD  
(mg/m2)
RD  
(mg/m2) 
Topoisomerase I inhibitors
Hotta et al71 NSCLC I untreated or  
treated
AMR 
CPT-11
1, 8 
1, 8 
3 45
100
40
100
Yanaihara et al57 NSCLC I untreated AMR 1–3 3 30. 25
CPT-11 1, 8 60 60
Oshita et al72 NSCLC I untreated AMR 1–3 2 40 35
CPT-11 1 60 60
Shibayama et al58 SCLC I untreated or  
treated
AMR 3–5 4 40 35
Topotean 1–5 0.75 0.75
Nogami et al73
 
SCLC
 
II
 
untreated or  
treated
AMR 3–5 3 – 35
Topotean 1–5   – 0.75
platinum agents
Yoshimura et al74 NSCLC I untreated AMR 1–3 3 30 30
CDDP 1 80 80
Ikeda et al75 NSCLC I treated AMR 1–3 3–4 30 25
CDDP 1–3 20 20
Ohe et al76 SCLC I/II untreated AMR 1–3 3 45 40
CDDP 1 60 60
Fukuda et al77 SCLC I untreated AMR 1–3 3 40 35
CBDCA 1 AUC5  AUC5
Inoue et al70 elderly  
SCLC
I untreated AMR
CBDCA
1–3
1
3 40
AUC4
35
AUC4
Abbreviations:  MTD,  maximum  tolerated  dose;  RD,  recommended  dose;  NSCLC,  non-small  cell  lung  cancer;  SCLC,  small  cell  lung  cancer;   
AMR, amrubicin; CPT-11, irinotecan; CDDP, cisplatin; CBDCA, carboplatin; AUC, area under curve.Amrubicin for second-line treatment of SCLC
Clinical Medicine Insights: Oncology 2011:5  31
a  lack  of  synergism  with  concurrent  exposure  to 
  topoisomerase I and II inhibitors.
platinum Agents and Amrubicin
We have identified five studies of AMR and platinum 
agents. The  combination  of  first  three  studies  was 
AMR and CDDP, and that of the last two studies was 
AMR  and  carboplatin  (CBDCA).  The  first  study, 
reported by our group, was a phase I study of AMR 
and  CDDP  in  patients  with  previously  untreated 
advanced  NSCLC.74  AMR  was  administered  on 
days 1–3, and CDDP was administered at a fixed dose 
of 80 mg/m2 on days 1, every 3 weeks. The MTD and 
recommended dose (RD) for AMR were determined 
to be at 30 mg/m2. The second was a phase I study of 
AMR and CDDP in patients with previously treated 
NSCLC.75 AMR was administered on days 1–3, and 
CDDP was administered at a fixed dose of 20 mg/m2 
on days 1–3, every 3 or 4 weeks. The MTD was deter-
mined to be at 30 mg/m2 for AMR . The recommended 
dose was determined to be 25 mg/m2 for AMR. The 
third was a phase I–II study of AMR and CDDP in 
previously untreated patients with ED-SCLC.76 AMR 
was administered on days 1–3 and CDDP on day 1, 
every 3 weeks. The MTD was determined to be at 
45 mg/m2 for AMR and 60 mg/m2 for CDDP. The 
RD was determined to be 40 mg/m2 for AMR and 
60 mg/m2 for CDDP. The RR at the recommended 
dose  was  87.8%  (36/41  patients).  The  MST  was 
13.6 months and the 1-year survival rate was 56.1%. 
Grade 3/4 neutropenia and leukopenia occurred in 
95.1% and 65.9% of patients, respectively. The forth 
was a phase I trial of AMR and CBDCA in previously 
untreated  patients  with  ED-SCLC.77  AMR  and 
CBDCA were administered by intravenous infusion 
on days 1, 2, and 3, and on day 1, respectively. The 
MTDs of AMR and CBDCA were determined to be 
40 mg/m2 and the AUC was 5. A dose of 35 mg/m2 
AMR and CBDCA at AUC 5 was recommended in 
this regimen. The DLTs included neutropenia, leuko-
penia,  thrombocytopenia,  febrile  neutropenia,  and 
liver dysfunction. Evaluation of the responses revealed 
two patients with CR, nine with PR (RR 73%), and 
the MST was 13.6 months. The fifth was a phase I 
trial  of AMR  combined  with  CBDCA  for  elderly 
patients with SCLC,70 and is described in the “Amru-
bicin Therapy for Elderly SCLC Patients” section.
In our pharmacological study, we established the 
relationships between AMR-OH and hematological 
toxicity during treatment with AMR alone, as well as 
during co-administration with CDDP, using a sigmoid 
Emax model for pharmacodynamic analysis.60 The sig-
moid  curve  for  co-administration  with  CDDP  was 
shifted to the left compared with that for AMR alone. 
This shift may indicate that patients treated with AMR 
and CDDP developed neutropenia more often than 
would be expected if they were treated with AMR 
alone. This mild additive effect in hematological tox-
icity is in agreement with clinical observations noted 
in  many  previous  reports:  patients  receiving  com-
bined treatment with AMR and CDDP experienced 
more profound myelotoxicity than those treated with 
AMR alone, and the dose of AMR for combined treat-
ment with CDDP was less than that used for AMR 
monotherapy.74-76
phase III studies
To  our  knowledge, AMR  is  currently  undergoing 
phase III clinical studies in one monotherapy trial 
and  two  double  combination  regimen  trials.  The 
monotherapy  trial  involves  patients  with  SCLC, 
after failure of first-line chemotherapy, comparing 
AMR with topotecan. The combination regimen tri-
als comprise a randomized, multicenter study com-
paring CPT-11 with CDDP versus AMR with CDDP 
in the treatment of ED-SCLC; and a study of AMR 
with CDDP versus VP-16 with CDDP in ED-SCLC 
patients.
Amrubicin Therapy for elderly  
scLc patients
In a first-line setting, AMR monotherapy for treating 
elderly  and  high-risk  patients  with  SCLC  has  been 
reported.78 A  dose  of  40  mg/m2  on  days  1–3  every 
3 weeks was feasible, and had a favorable anticancer 
effect with an RR of 73%. Another phase I study used a 
combination therapy of AMR and CBDCA in previ-
ously  untreated  elderly  SCLC  patients.70  DLTs  were 
observed  in  all  three  patients  at  level  1  (AMR  at 
40 mg/m2 and CBDCA at AUC 4.0) with grade 4 neu-
tropenia or thrombocytopenia, or grade 3 diarrhea. The 
MTD  of  this  combination  therapy  was  AMR  at   
40 mg/m2 and CBDCA at AUC 4.0, and the recom-
mended dose for a phase II trial is AMR at 35 mg/m2 Kimura et al
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and CBDCA at AUC 4.0. There are no reports of a 
second-line  setting  for  AMR  treatment  of  elderly 
patients with SCLC.
Future Approaches
Combination regimens that comprise agents with dif-
ferent mechanisms of action can result in synergistic 
antitumor activity and may overcome resistance to che-
motherapy. In SCLC, combination chemotherapy gen-
erally yields higher overall RRs than does single agent 
therapy. However, care must be taken in the selection of 
agents to avoid overlapping toxicities that may adversely 
affect quality of life, especially in patients with exten-
sive SCLC. To our knowledge, AMR is undergoing 
phase I or I–II clinical trials in combination regimens, 
including AMR plus TS-1 (tegafur, gimeracil and otera-
cil potassium), AMR plus nedaplatin, and AMR after 
concurrent VP-16 and CDDP plus accelerated hyper-
fractionated thoracic radiotherapy.
Unfortunately, it has been impossible in this review 
to cite all the references referring to the use of AMR 
in SCLC; likewise, we have not discussed the clinical 
trials of AMR performed in NSCLC patients. We have 
not  discussed  the  downstream  metabolites  of 
AMR-OH.  The  detailed  molecular  mechanisms  of 
how  AMR  induces  apoptosis  in  cancer  cells  are 
unclear. Finally, most of the clinical trials with AMR 
have been performed in Japan: more trials conducted 
outside Japan are warranted.
conclusions
It is clear that AMR, with its predictable and mana-
geable toxicities, is one of the most attractive agents 
for  the  treatment  of  chemotherapy-sensitive  and 
-  refractory  relapsed  SCLC.  Numerous  studies  are 
ongoing in an attempt to define the applicability of 
AMR as a single agent or in combination chemother-
apy  for  patients  with  SCLC.  These  clinical  trials, 
including phase III studies, will clarify the status of 
AMR in the treatment of SCLC.
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